Berberine — Isoquinoline alkaloid / AMPK activator
Berberine activates AMP-activated protein kinase (AMPK), a cellular energy sensor that mimics many effects of metformin and caloric restriction. AMPK activation: inhibits hepatic glucose production, increases insulin sensitivity, activates GLUT4 translocation, reduces lipogenesis, increases mitochondrial biogenesis. Additionally modulates gut microbiome (increases Akkermansia, Bifidobacterium), inhibits PCSK9 (LDL-lowering), downregulates NF-κB (anti-inflammatory), and has antimicrobial/anti-parasitic properties. Multiple meta-analyses demonstrate efficacy for T2DM, dyslipidemia, and PCOS comparable to first-line medications.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Isoquinoline alkaloid / AMPK activator
Mechanism of Action
Berberine activates AMP-activated protein kinase (AMPK), a cellular energy sensor that mimics many effects of metformin and caloric restriction. AMPK activation: inhibits hepatic glucose production, increases insulin sensitivity, activates GLUT4 translocation, reduces lipogenesis, increases mitochondrial biogenesis. Additionally modulates gut microbiome (increases Akkermansia, Bifidobacterium), inhibits PCSK9 (LDL-lowering), downregulates NF-κB (anti-inflammatory), and has antimicrobial/anti-parasitic properties. Multiple meta-analyses demonstrate efficacy for T2DM, dyslipidemia, and PCOS comparable to first-line medications.
Regulatory Status
OTC dietary supplement. Not FDA-approved for any indication. Prescription form not available in US. Approved as medication in China.
Evidence Level
Moderate-High — multiple RCTs and meta-analyses for T2DM, dyslipidemia, PCOS. ADA position statement acknowledges berberine's glucose-lowering evidence but does not formally endorse as first-line.